文献速递慢性肾脏病水电解质与酸碱

帕替罗姆治疗慢性肾脏病合并高钾血症与高磷血症患者:3项临床试验的事后分析

Patiromer Treatment in Patients With CKD, Hyperkalemia, and Hyperphosphatemia: A Post Hoc Analysis of 3 Clinical Trials.
PubMed 文献 · Am J Kidney Dis · 2023-03-23

该研究汇总AMETHYST-DN、OPAL-HK和TOURMALINE三项试验的578例慢性肾脏病合并高钾血症患者数据,事后分析帕替罗姆对血磷的影响。基线高磷血症患者86例(14.9%),其中75.6%为CKD 4/5期。治疗4周后,基线血磷和血钾均升高的患者血磷平均降低0.62 mg/dL、血钾平均降低0.71 mEq/L,血镁降低0.25 mg/dL,血钙保持不变。

要点

  • 578例CKD合并高钾血症患者中,86例(14.9%)基线存在高磷血症。
  • 基线血磷和血钾均升高的患者,帕替罗姆治疗4周后血磷平均降低0.62 mg/dL、血钾平均降低0.71 mEq/L。
  • 帕替罗姆总体耐受良好,未发生被认为与帕替罗姆相关的严重不良事件。

核心结论

  • 在非透析依赖性CKD合并高钾血症和高磷血症患者中,帕替罗姆治疗2周后血磷和血钾降至正常范围,并在4周治疗期间维持降低。
  • 需要未来的对照试验来确定帕替罗姆是否可用于降低CKD合并高磷血症的高钾血症患者的血钾和血磷。

研究设计与样本

  • 对AMETHYST-DN、OPAL-HK和TOURMALINE三项帕替罗姆临床试验的个体水平数据进行事后汇总分析。
  • 纳入578例慢性肾脏病合并高钾血症患者,帕替罗姆剂量为8.4-33.6 g/天。
  • 采用描述性统计学汇总三项研究的研究结局数据。

主要发现

  • 578例参与者中,86例(14.9%)基线存在高磷血症,其中75.6%(65/86)为CKD 4/5期;血磷≤4.5 mg/dL的492例中31.1%(153/492)为CKD 4/5期。
  • 基线血磷和血钾均升高的患者,帕替罗姆治疗4周后血磷平均±SD降低0.62±1.09 mg/dL,血钾平均±SD降低0.71±0.51 mEq/L。
  • 上述患者血镁平均±SD降低0.25±0.23 mg/dL,血钙保持不变;血镁和血钙均保持在正常范围内。
  • 帕替罗姆总体耐受良好,未发生被认为与帕替罗姆相关的严重不良事件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 这些是事后分析。
  • 由于原始研究的设计,未进行安慰剂对照。
  • 随访期限于4周。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Patients with chronic kidney disease (CKD), hyperkalemia (serum potassium [sK+]>5.0 mEq/L), and hyperphosphatemia experience poor clinical outcomes. Patiromer, a potassium binder that uses calcium as the exchange ion, may also reduce serum phosphorus (sP). We characterized the effect of patiromer on sP in patients with CKD, hyperkalemia, and hyperphosphatemia. STUDY DESIGN: A post hoc pooled analysis of individual-level data from the AMETHYST-DN, OPAL-HK, and TOURMALINE trials of patiromer. SETTING & PARTICIPANTS: Patients with CKD and hyperkalemia. EXPOSURE: Patients treated with patiromer (8.4-33.6 g/day). OUTCOME: Mean changes from baseline in sP, sK+, serum calcium (sCa2+), and serum magnesium (sMg2+) after 2 and 4 weeks of treatment. ANALYTICAL APPROACH: Descriptive statistics to summarize pooled data on the study outcomes from the 3 studies. RESULTS: We included 578 patients in the analysis. Of these participants, 86 patients (14.9%) had baseline hyperphosphatemia of whom 75.6% (65 of 86) had CKD stage 4/5 and 31.1% (153 of 492) with sP≤4.5mg/dL had CKD stage 4/5. Among the patients with elevated sP and sK+at baseline, the mean±SD reduction in sP and sK+after 4 weeks of patiromer treatment was-0.62±1.09mg/dL and-0.71± 0.51 mEq/L, respectively. Additionally, the mean±SD reduction in sMg2+in these patients was -0.25±0.23mg/dL while sCa2+remained unchanged. Both sMg2+and sCa2+remained within the normal range. Patiromer was generally well tolerated, and no serious adverse events were considered related to patiromer. LIMITATIONS: These were post hoc analyses, no placebo comparison was performed due to the design of the original studies, and the follow-up period was limited to 4 weeks. CONCLUSIONS: Reductions in sP and sK+to the normal range were observed after 2 weeks of patiromer treatment, and the reduction was sustained during 4 weeks of treatment among patients with non-dialysis-dependent CKD, hyperkalemia, and hyperphosphatemia. Future controlled trials are needed to establish if patiromer is useful to reduce both sK+and sP in hyperkalemic patients with CKD and hyperphosphatemia.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Bushinsky DA, Budden JJ, Kalra PA, et al. Patiromer Treatment in Patients With CKD, Hyperkalemia, and Hyperphosphatemia: A Post Hoc Analysis of 3 Clinical Trials. Am J Kidney Dis. 2023. PMID: 36965827. doi:10.1053/j.ajkd.2023.01.444

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。